Academic health system Emory Healthcare is partnering with Atropos Health, a company that translates real-world clinical data into real-world evidence, to advance medication formulary decisions and protocols. 

Emory is piloting a program that aims to advance patient care by allowing clinical questions to be answered in real time using Atropos' platform.  

The Atropos Evidence Network allows Emory users to run studies on national datasets and local Emory data. Clinicians can also use Atropos' Green Button to access real-world evidence, generating results through supervised evidence development or a fully automated generative AI version (ChatRWD).

ChatRWD is an large language model (LLM)-powered chat tool for clinical research that aims to eliminate hallucination risk by employing the company's real-world data platform, GENEVA OS. 

"Atropos Health provides a means to answer questions not specifically or robustly answered in published data; Atropos surfaces practice-based evidence where evidence-based medicine does not exist," Dr. Alistair Erskine, enterprise chief information and digital officer for Emory Healthcare and Emory University, said in a statement. 

"We are already seeing early success as one of our users explored real-world outcomes, adverse events and costs of a drug that will improve our drug therapy protocol and benefit Emory patients."

THE LARGER TREND

In January, Atropos announced a partnership with xCures, an AI-powered healthcare data retrieval company, to harness RWE-based insights to support patient care. The collaboration will leverage AI, the Atropos Evidence Network and the xCures Platform to develop and deploy prognostic and decision-support tools for care providers.

It also partnered with pharma giant Merck to generate RWE, replicate studies, and produce rapid insights and analytics on real-world data. 

Last year, Atropos secured $33 million in Series B funding and announced that healthcare data analytics company Arcadia joined its health portfolio, giving Arcadia's provider customers and life sciences users access to Atropos' offerings. 

Through the partnership, Arcadia joined Atropos' Evidence Network, allowing its users access to Atropos' portfolio of applications to support clinical decision-making in value-based care. 

In 2023, Atropios announced a partnership with data-sharing technology platform Datavant to allow each company's members to access the other company's offerings. 

In 2022, Atropos secured $14 million in a Series A funding round.